GLP1 receptor agonist overcomes SGLT2 inhibitor-related overeating

Nat Rev Endocrinol. 2022 Sep;18(9):523-524. doi: 10.1038/s41574-022-00722-2.

Author

Matthias Blüher^{1

2}

Affiliations

¹ Helmholtz Institute for Metabolic, Obesity and Vascular Research, University of Leipzig, Leipzig, Germany. matthias.blueher@helmholtz-muenchen.de.
² Department of Endocrinology, Nephrology, Rheumatology, University of Leipzig, Leipzig, Germany. matthias.blueher@helmholtz-muenchen.de.

PMID: 35821108
DOI: 10.1038/s41574-022-00722-2

No abstract available

Publication types

Comment

MeSH terms

Diabetes Mellitus, Type 2* / drug therapy
Glucagon-Like Peptide-1 Receptor Agonists
Humans
Hyperphagia
Hypoglycemic Agents / adverse effects
Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use

Substances

Hypoglycemic Agents
Sodium-Glucose Transporter 2 Inhibitors
Glucagon-Like Peptide-1 Receptor Agonists